Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study Nick Scott, PhD, Anna Palmer, BBiomedSc, Christopher Morgan, FRACP, Prof Olufunmilayo Lesi, MD, Prof C Wendy Spearman, PhD, Prof Mark Sonderup, MMED, Prof Margaret Hellard, PhD The Lancet Global Health Volume 6, Issue 6, Pages e659-e667 (June 2018) DOI: 10.1016/S2214-109X(18)30219-5 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 1 Model schematic HBV3=three-dose HBV vaccination schedule. The Lancet Global Health 2018 6, e659-e667DOI: (10.1016/S2214-109X(18)30219-5) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 2 Cost-effectiveness of the CTC strategy The estimated DALYs averted and additional costs per 1000 births at the (A) regional and (B, C) country level after the CTC hepatitis B virus birth dose vaccination strategy was implemented in the model. IQRs for regions are from the Monte Carlo uncertainty analysis. Country-specific CIs are available in the appendix. DALYs=disability-adjusted life-years. CTC=cold temperature chain. The Lancet Global Health 2018 6, e659-e667DOI: (10.1016/S2214-109X(18)30219-5) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions
Figure 3 Sensitivity analysis for the cost-effectiveness of the CTC hepatitis B virus vaccine strategy, by use of the global average costs and epidemiological data as a base scenario The effect of alternative assumptions about (A) the HBsAg prevalence (from a base of 3·84%), (B) the warm vaccine effectiveness relative to the cold chain vaccine (from a base of equal effectiveness), (C) the additional cost of the cold temperature chain delivered vaccines (from a base of US$16·14), (D) the additional day 1 birth dose coverage achievable (from a base of 10%), and (E) the existing cold chain birth dose vaccine coverage (from a base of 67%). DALYs=disability-adjusted life-years. The Lancet Global Health 2018 6, e659-e667DOI: (10.1016/S2214-109X(18)30219-5) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions